Clinical trials
Withdrawn Burkitt Lymphoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 19 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Alliance for Clinical Trials in Oncology | 1 |
| Dorothy Sipkins, MD, PhD | 1 |
| Enzon Pharmaceuticals, Inc. | 1 |
| Hoag Memorial Hospital Presbyterian | 1 |
| Kevin McNerney | 1 |
| Mayo Clinic | 1 |
| Roswell Park Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Burkitt Lymphoma | 19 |
| Lymphoma, Mantle-Cell | 11 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 |
| Lymphoma, Follicular | 10 |
| Lymphoma, Large B-Cell, Diffuse | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 |
| Lymphoma, B-Cell, Marginal Zone | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Lymphoma | 8 |
| Lymphoma, Large-Cell, Immunoblastic | 8 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.